Visx hearing date fixed as surgeon calls for laser halt
This article was originally published in Clinica
Executive Summary
The Federal Trade Commission has set October 13 as the date for its investigation hearings against Pillar Point, the joint venture company made up of Visx and Summit Technology over the two companies' alleged overcharging In the laser eye surgery market. In addition the FTC is alleging that Visx's basic patents were fraudulently obtained. The hearings will begin on October 13.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.